Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APL510
- Development stage
- Phase 2
- Lead developer
- Alliance Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
APL510 is a sustained-release (prolonged-release) formulation of melatonin, a naturally occurring hormone that regulates circadian rhythms and the sleep-wake cycle. Developed by Alliance Pharmaceuticals, APL510 acts as an agonist at the melatonin MT1 and MT2 receptors to promote sleep and normalize circadian patterns. The drug was specifically investigated in a Phase II double-blind, placebo-controlled, randomized, cross-over clinical study in elderly subjects with insomnia, evaluating the efficacy of 1.5 mg and 3.0 mg doses in normalizing sleep patterns and improving sleep quality.
- Other names
- sustained-release melatoninprolonged-release melatonin
02
Targets
MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)
Beyond the preview
Go deeper on APL510.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APL510.